Pulmonary Alveolar Proteinosis
14
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
A National Registry For Pulmonary Alveolar Proteinosis
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis
Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.